HUE028458T2 - High affinity anti-human IgE antibodies - Google Patents
High affinity anti-human IgE antibodies Download PDFInfo
- Publication number
- HUE028458T2 HUE028458T2 HUE11170255A HUE11170255A HUE028458T2 HU E028458 T2 HUE028458 T2 HU E028458T2 HU E11170255 A HUE11170255 A HU E11170255A HU E11170255 A HUE11170255 A HU E11170255A HU E028458 T2 HUE028458 T2 HU E028458T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibody
- ser
- thr
- ige
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44422903P | 2003-02-01 | 2003-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE028458T2 true HUE028458T2 (en) | 2016-12-28 |
Family
ID=32850839
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE11170255A HUE028458T2 (en) | 2003-02-01 | 2004-02-02 | High affinity anti-human IgE antibodies |
| HUE08104978A HUE028407T2 (hu) | 2003-02-01 | 2004-02-02 | Nagy affinitással rendelkezõ humán IgE antitestek |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08104978A HUE028407T2 (hu) | 2003-02-01 | 2004-02-02 | Nagy affinitással rendelkezõ humán IgE antitestek |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7531169B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2000481B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP4764334B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN1829806A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2004209638B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2514840C (cg-RX-API-DMAC7.html) |
| CY (2) | CY1118063T1 (cg-RX-API-DMAC7.html) |
| DK (2) | DK2407485T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2566778T3 (cg-RX-API-DMAC7.html) |
| HU (2) | HUE028458T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL176940A (cg-RX-API-DMAC7.html) |
| MX (1) | MX338940B (cg-RX-API-DMAC7.html) |
| PT (1) | PT2000481E (cg-RX-API-DMAC7.html) |
| SI (2) | SI2407485T1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2004070010A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| WO2004070010A2 (en) * | 2003-02-01 | 2004-08-19 | Tanox, Inc. | A method for generating high affinity antibodies |
| US20060234296A1 (en) * | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
| MX361174B (es) | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| JP2008507474A (ja) * | 2004-02-02 | 2008-03-13 | タノックス インコーポレイテッド | 新規のIgEエピトープの同定 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006055704A2 (en) * | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
| US8137670B2 (en) * | 2005-09-29 | 2012-03-20 | Medimmune, Llc | Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| AR065368A1 (es) | 2007-02-15 | 2009-06-03 | Astrazeneca Ab | Anticuerpos para moleculas de ige |
| PL2132230T3 (pl) | 2007-03-22 | 2014-09-30 | Genentech Inc | Apoptotyczne przeciwciała anty-IgE wiążące IgE związaną z błoną |
| DE102007052281A1 (de) * | 2007-11-02 | 2009-05-07 | Zenteris Gmbh | Einschritt-Multiplex-Immuntest |
| WO2009072660A1 (ja) | 2007-12-03 | 2009-06-11 | Kabushiki Kaisya Advance | 抗体作製方法 |
| US8633139B2 (en) | 2007-12-21 | 2014-01-21 | Abbvie Biotherapeutics Inc. | Methods of screening complex protein libraries to identify altered properties |
| CN101230103B (zh) * | 2008-03-25 | 2011-09-07 | 中国医药集团总公司四川抗菌素工业研究所 | 一全人源重组抗-IgE抗体 |
| PT3190128T (pt) | 2008-09-17 | 2019-02-07 | Xencor Inc | Composições e métodos para tratar distúrbios mediados pela ige |
| US9187568B2 (en) | 2009-05-07 | 2015-11-17 | Stallergenes S.A. | Use of IgG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and manifestations via the mucosal route |
| DK2494356T3 (en) | 2009-10-26 | 2017-05-15 | Genentech Inc | ASSAYS FOR THE DETECTION OF ANTIBODIES SPECIFIC TO THERAPEUTIC ANTI-IGE ANTIBODIES AND THEIR USE OF ANAPHYLAXY |
| MX2012011629A (es) * | 2010-04-07 | 2013-03-05 | Abbvie Inc | Proteinas de union a tnf-alfa. |
| AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| WO2013116287A1 (en) | 2012-01-31 | 2013-08-08 | Genentech, Inc. | Anti-ig-e m1' antibodies and methods using same |
| SI2849723T1 (sl) | 2012-05-18 | 2018-09-28 | Genentech, Inc. | Formulacije z visoko koncentracijo monoklonskih protiteles |
| KR102502640B1 (ko) | 2012-08-21 | 2023-02-23 | 사노피 바이오테크놀로지 | Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법 |
| CN118286417A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| TWI755763B (zh) | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法 |
| US10196458B2 (en) | 2013-07-26 | 2019-02-05 | The Regents Of The University Of California | Anti-immunoglobulin E antibodies and methods of using thereof |
| CN106471372B (zh) | 2014-01-29 | 2019-10-11 | 通用电气健康护理生物科学股份公司 | 用于相互作用分析的方法和系统 |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| SG11201607046VA (en) * | 2014-06-17 | 2016-10-28 | Academia Sinica | HUMANIZED ANTI-IgE ANTIBODIES THAT CROSSLINK CD23 ON B LYMPHOCYTES BUT DO NOT SENSITIZE MAST CELLS |
| PT3110848T (pt) | 2014-09-24 | 2024-03-05 | Regeneron Pharma | Métodos para tratamento de infeção cutânea por administração de um antagonista do il-4r |
| JP6829194B2 (ja) * | 2014-10-24 | 2021-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Vh−vlドメイン間角度に基づく抗体ヒト化の方法 |
| CA3246946A1 (en) | 2014-11-14 | 2025-11-29 | Sanofi Biotechnology | Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist |
| KR102872485B1 (ko) | 2016-09-01 | 2025-10-20 | 리제너론 파아마슈티컬스, 인크. | Il-4r 길항제를 투여함에 의해 알레르기를 예방하거나 치료하기 위한 방법 |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| AU2017382281B2 (en) | 2016-12-22 | 2024-07-11 | Genentech, Inc. | Methods and formulations for reducing reconstitution time of lyophilized polypeptides |
| CA3049967C (en) * | 2017-01-06 | 2024-10-01 | The Regents Of The University Of California | ANTI-IgE ANTIBODIES: THERAPIES AND ASSOCIATED METHODS AND COMPOSITIONS |
| WO2019028367A1 (en) | 2017-08-04 | 2019-02-07 | Regeneron Pharmaceuticals, Inc. | METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES |
| PT3515465T (pt) | 2017-08-18 | 2024-03-04 | Regeneron Pharma | Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r |
| US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| KR20220098056A (ko) | 2018-02-09 | 2022-07-08 | 제넨테크, 인크. | 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법 |
| CA3094749A1 (en) * | 2018-03-26 | 2019-10-03 | Novartis Ag | Methods of treating chronic spontaneous urticaria using ligelizumab |
| MX2020012064A (es) | 2018-05-13 | 2021-04-13 | Regeneron Pharma | Metodos para tratar la dermatitis atopica administrando un inhibidor de il-4r. |
| CN109651510B (zh) * | 2018-12-04 | 2023-03-24 | 上海长征医院 | 抗Eno1抗体及其用途 |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| GB2589049C (en) | 2019-04-11 | 2024-02-21 | argenx BV | Anti-IgE antibodies |
| KR20220034878A (ko) | 2019-07-16 | 2022-03-18 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| US11504426B2 (en) | 2019-08-05 | 2022-11-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist |
| JP7736667B2 (ja) | 2019-08-05 | 2025-09-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Il-4rアンタゴニストを投与することによるアトピー性皮膚炎の治療方法 |
| JP2021141861A (ja) * | 2020-03-13 | 2021-09-24 | 富士フイルム和光純薬株式会社 | 抗原に対する親和力が向上した抗体のスクリーニング方法および製造方法 |
| WO2021255621A1 (en) | 2020-06-15 | 2021-12-23 | Novartis Ag | Treatment of food allergy using anti-ige antibodies |
| EP4305190A4 (en) | 2021-03-11 | 2025-03-26 | Iggenix, Inc. | METHODS AND SYSTEMS FOR PREDICTING AN ALLERGIC REACTION |
| US20240269279A1 (en) | 2021-06-14 | 2024-08-15 | Novartis Ag | PHARMACEUTICAL FORMULATION CONTAINING AN ANTI-IgE ANTIBODY |
| US20260035484A1 (en) * | 2021-10-29 | 2026-02-05 | Longbio Pharma (Suzhou) Co., Ltd. | Isolated antigen binding protein and use thereof |
| JP2024544380A (ja) | 2021-12-14 | 2024-11-29 | ノバルティス アーゲー | 抗IgE抗体を使用したアレルギー反応の治療 |
| CN116143932B (zh) * | 2022-12-07 | 2025-02-11 | 南开大学 | 一种针对IgE的抗体或其抗原结合片段以及Fc变体 |
| CN116359516A (zh) * | 2023-04-04 | 2023-06-30 | 郑州安图生物工程股份有限公司 | 检测血清总IgE含量的试剂盒及应用 |
| CN119490594B (zh) * | 2023-08-15 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 一种抗免疫球蛋白e的抗体及其应用 |
| CN119745868B (zh) * | 2024-11-21 | 2026-04-07 | 广州创瑞健康科技有限公司 | 一种人免疫球蛋白e拮抗剂、筛选方法以及应用 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268176A (en) * | 1916-11-29 | 1918-06-04 | Us Slicing Machine Co | Power mechanism for slicing-machines. |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5614611A (en) | 1987-12-31 | 1997-03-25 | Tanox Biosystems, Inc. | Humanized monoclonal antibodies binding to IgE-bearing B cells but not basophils |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5428133A (en) | 1987-12-31 | 1995-06-27 | Tanox Biosystems, Inc. | Chimeric anti-human IgE-monoclonal antibody which binds to secreted IgE and membrane-bound IgE expressed by IgE-expressing B cells but notto IgE bound to FC receptors on basophils |
| EP0617127A1 (en) | 1987-12-31 | 1994-09-28 | Tanox Biosystems, Inc. | Antigenic epitopes on B cell-bound IgE Immunoglobulins |
| US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| CA2018228C (en) | 1989-06-05 | 1996-02-27 | Nancy L. Parenteau | Cell culture systems and media |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| CA2140933A1 (en) | 1992-08-21 | 1994-02-22 | Paula M. Jardieu | Method for treating an lfa-1 mediated disorder |
| EP0589840B1 (en) * | 1992-09-24 | 2004-04-14 | Novartis AG | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| ATE139900T1 (de) | 1992-11-13 | 1996-07-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| US5994511A (en) * | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| US6172213B1 (en) * | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
| CN1289253A (zh) * | 1998-01-29 | 2001-03-28 | 泰诺士公司 | 以lgE拮抗剂治疗特应性皮炎 |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| US20050169909A1 (en) | 2004-02-02 | 2005-08-04 | Sanjaya Singh | Identification of novel IgE epitopes |
| WO2004070010A2 (en) * | 2003-02-01 | 2004-08-19 | Tanox, Inc. | A method for generating high affinity antibodies |
| US20060234296A1 (en) | 2003-02-01 | 2006-10-19 | Sanjaya Singh | Method for generating high affinity antibodies |
-
2004
- 2004-02-02 WO PCT/US2004/002892 patent/WO2004070010A2/en not_active Ceased
- 2004-02-02 AU AU2004209638A patent/AU2004209638B2/en not_active Expired
- 2004-02-02 US US10/544,056 patent/US7531169B2/en not_active Expired - Lifetime
- 2004-02-02 PT PT08104978T patent/PT2000481E/pt unknown
- 2004-02-02 EP EP08104978.5A patent/EP2000481B1/en not_active Expired - Lifetime
- 2004-02-02 EP EP04707380A patent/EP1592777A4/en not_active Withdrawn
- 2004-02-02 HU HUE11170255A patent/HUE028458T2/en unknown
- 2004-02-02 AU AU2004209637A patent/AU2004209637A1/en not_active Abandoned
- 2004-02-02 ES ES11170255.1T patent/ES2566778T3/es not_active Expired - Lifetime
- 2004-02-02 SI SI200432311A patent/SI2407485T1/sl unknown
- 2004-02-02 EP EP11170255.1A patent/EP2407485B1/en not_active Expired - Lifetime
- 2004-02-02 ES ES08104978.5T patent/ES2575547T3/es not_active Expired - Lifetime
- 2004-02-02 JP JP2006503245A patent/JP4764334B2/ja not_active Expired - Lifetime
- 2004-02-02 EP EP04707368A patent/EP1592776A4/en not_active Withdrawn
- 2004-02-02 CN CNA2004800082701A patent/CN1829806A/zh active Pending
- 2004-02-02 CA CA2514840A patent/CA2514840C/en not_active Expired - Lifetime
- 2004-02-02 SI SI200432324A patent/SI2000481T1/sl unknown
- 2004-02-02 WO PCT/US2004/002894 patent/WO2004070011A2/en not_active Ceased
- 2004-02-02 HU HUE08104978A patent/HUE028407T2/hu unknown
- 2004-02-02 CN CN201210316908.4A patent/CN102993306B/zh not_active Expired - Lifetime
- 2004-02-02 DK DK11170255.1T patent/DK2407485T3/en active
- 2004-02-02 JP JP2006503243A patent/JP2006516408A/ja active Pending
- 2004-02-02 DK DK08104978.5T patent/DK2000481T3/en active
- 2004-02-02 CN CN2004800070117A patent/CN1771338B/zh not_active Expired - Lifetime
- 2004-02-02 CA CA002514839A patent/CA2514839A1/en not_active Abandoned
- 2004-07-29 MX MX2011007343A patent/MX338940B/es unknown
-
2006
- 2006-07-18 IL IL176940A patent/IL176940A/en active IP Right Grant
-
2009
- 2009-03-27 US US12/413,014 patent/US8252284B2/en not_active Expired - Fee Related
-
2010
- 2010-09-09 JP JP2010202452A patent/JP2011042654A/ja active Pending
-
2011
- 2011-04-26 JP JP2011098737A patent/JP5296138B2/ja not_active Expired - Lifetime
- 2011-05-03 AU AU2011202021A patent/AU2011202021B2/en not_active Expired
-
2012
- 2012-07-27 US US13/559,938 patent/US8604171B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 US US14/074,309 patent/US9156908B2/en not_active Expired - Lifetime
-
2016
- 2016-04-04 CY CY20161100269T patent/CY1118063T1/el unknown
- 2016-06-09 CY CY20161100504T patent/CY1117617T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2000481T3 (en) | High affinity anti-human IgE antibodies | |
| AU2009202408A1 (en) | Identification of novel IgE epitopes | |
| US20110200604A1 (en) | IDENTIFICATION OF NOVEL IgE EPITOPES | |
| AU2012261739A1 (en) | Identification of novel IgE epitopes | |
| US20060234296A1 (en) | Method for generating high affinity antibodies | |
| HK1166330B (en) | High affinity anti-human ige antibodies | |
| HK1126788B (en) | High affinity anti-human ige antibodies | |
| AU2013263817A1 (en) | High affinity anti-human IgE antibodies | |
| HK1085771B (en) | High affinity anti-human ige antibodies |